{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:08:50Z","timestamp":1789826930711,"version":"4.0.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"UGC-DAE-CSR, Kolkata, India","award":["No. KC\/CRS\/19\/RB-04\/1047"],"award-info":[{"award-number":["No. KC\/CRS\/19\/RB-04\/1047"]}]},{"name":"UGC-DAE-CSR, Kolkata, India","award":["No. KC\/CRS\/19\/RB-04\/1047"],"award-info":[{"award-number":["No. KC\/CRS\/19\/RB-04\/1047"]}]},{"name":"UGC-DAE-CSR, Kolkata, India","award":["No. KC\/CRS\/19\/RB-04\/1047"],"award-info":[{"award-number":["No. KC\/CRS\/19\/RB-04\/1047"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00280-024-04709-w","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T16:45:45Z","timestamp":1724345145000},"page":"685-706","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Combination of ionizing radiation and 2-thio-6-azauridine induces cell death in radioresistant triple negative breast cancer cells by downregulating CD151 expression"],"prefix":"10.1007","volume":"94","author":[{"given":"Rakshmitha","family":"Marni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manas","family":"Malla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindita","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali Krishna","family":"Voonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partha Sarathi","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"KGK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama Rao","family":"Malla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"issue":"35","key":"4709_CR1","doi-asserted-by":"publisher","first-page":"e4614","DOI":"10.1097\/MD.0000000000004614","volume":"95","author":"ML Plasilova","year":"2016","unstructured":"Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR (2016) Features of triple-negative breast cancer: analysis of 38,813 cases from the national cancer database. Medicine 95(35):e4614","journal-title":"Medicine"},{"issue":"1","key":"4709_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan J-J, Bian X-W, Yu S-c (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22(1):61. https:\/\/doi.org\/10.1186\/s13058-020-01296-5","journal-title":"Breast Cancer Res"},{"issue":"1","key":"4709_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y (2022) Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol 15(1):121. https:\/\/doi.org\/10.1186\/s13045-022-01341-0","journal-title":"J Hematol Oncol"},{"issue":"6","key":"4709_CR4","first-page":"685","volume":"15","author":"J Grozdanovic","year":"1968","unstructured":"Grozdanovic J, V\u00edch Z, Truxov\u00e1 G (1968) The combined effect of 6-azauridine and irradiation in vivo and in vitro. II. The nucleic acid livel in the ehrlich ascitic carcinoma cells after repeated applications of 6-AzUR and irradiation in vitro. Neoplasma 15(6):685\u2013687","journal-title":"Neoplasma"},{"issue":"6","key":"4709_CR5","first-page":"601","volume":"17","author":"J Grozdanovic","year":"1970","unstructured":"Grozdanovic J, V\u00edch Z, Truxov\u00e1 G, Kratochv\u00edl J (1970) Combined effect of 6-azauridine and irradiation in vivo and in vitro. VI. Nuclear diameters of Ehrlich ascites carcinoma cells after repeated irradiation and 6-AzUR application. Neoplasma 17(6):601\u2013606","journal-title":"Neoplasma"},{"issue":"4","key":"4709_CR6","first-page":"535","volume":"12","author":"E Magdon","year":"1971","unstructured":"Magdon E (1971) Effect of 6-azauridine in the irradiation of tumors. Radiol Diagn (Berl) 12(4):535\u2013544","journal-title":"Radiol Diagn (Berl)"},{"key":"4709_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.canlet.2020.10.016","volume":"497","author":"X Bai","year":"2021","unstructured":"Bai X, Ni J, Beretov J, Graham P, Li Y (2021) Triple-negative breast cancer therapeutic resistance: where is the Achilles\u2019 heel? Cancer Lett 497:100\u2013111. https:\/\/doi.org\/10.1016\/j.canlet.2020.10.016","journal-title":"Cancer Lett"},{"key":"4709_CR8","doi-asserted-by":"publisher","first-page":"103566","DOI":"10.1016\/j.critrevonc.2021.103566","volume":"169","author":"V Bhat","year":"2022","unstructured":"Bhat V, Pellizzari S, Allan AL, Wong E, Lock M, Brackstone M, Lohmann AE, Cescon DW, Parsyan A (2022) Radiotherapy and radiosensitization in breast cancer: molecular targets and clinical applications. Crit Rev Oncol Hematol 169:103566. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103566","journal-title":"Crit Rev Oncol Hematol"},{"key":"4709_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215380","author":"A Barcellini","year":"2021","unstructured":"Barcellini A, Loap P, Murata K, Villa R, Kirova Y, Okonogi N, Orlandi E (2021) PARP inhibitors in combination with radiotherapy: to do or not to do? Cancers. https:\/\/doi.org\/10.3390\/cancers13215380","journal-title":"Cancers"},{"issue":"4","key":"4709_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.joim.2021.01.001","volume":"19","author":"EWC Chan","year":"2021","unstructured":"Chan EWC, Wong SK, Chan HT (2021) An overview on the chemistry, pharmacology and anticancer properties of tetrandrine and fangchinoline (alkaloids) from Stephania tetrandra roots. J Integrat Med 19(4):311\u2013316. https:\/\/doi.org\/10.1016\/j.joim.2021.01.001","journal-title":"J Integrat Med"},{"issue":"2","key":"4709_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/ppo.0000000000000369","volume":"25","author":"MK Khan","year":"2019","unstructured":"Khan MK, Nasti TH, Buchwald ZS, Weichselbaum RR, Kron SJ (2019) Repurposing drugs for cancer radiotherapy: early successes and emerging opportunities. Cancer J (Sudbury, Mass) 25(2):106\u2013115. https:\/\/doi.org\/10.1097\/ppo.0000000000000369","journal-title":"Cancer J (Sudbury, Mass)"},{"issue":"1","key":"4709_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12894-021-00856-x","volume":"21","author":"BAS Bibby","year":"2021","unstructured":"Bibby BAS, Thiruthaneeswaran N, Yang L, Pereira RR, More E, McArt DG, O\u2019Reilly P, Bristow RG, Williams KJ, Choudhury A, West CML (2021) Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer. BMC Urol 21(1):96. https:\/\/doi.org\/10.1186\/s12894-021-00856-x","journal-title":"BMC Urol"},{"key":"4709_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10040200","author":"M \u00c1valos-Moreno","year":"2020","unstructured":"\u00c1valos-Moreno M, L\u00f3pez-Tejada A, Blaya-C\u00e1novas JL, Cara-Lupia\u00f1ez FE, Gonz\u00e1lez-Gonz\u00e1lez A, Lorente JA, S\u00e1nchez-Rovira P, Granados-Principal S (2020) Drug repurposing for triple-negative breast cancer. J Pers Med. https:\/\/doi.org\/10.3390\/jpm10040200","journal-title":"J Pers Med"},{"key":"4709_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.antiviral.2018.04.004","volume":"154","author":"KL Seley-Radtke","year":"2018","unstructured":"Seley-Radtke KL, Yates MK (2018) The evolution of nucleoside analogue antivirals: a review for chemists and non-chemists. Part 1: early structural modifications to the nucleoside scaffold. Antiviral Res 154:66\u201386. https:\/\/doi.org\/10.1016\/j.antiviral.2018.04.004","journal-title":"Antiviral Res"},{"issue":"2","key":"4709_CR15","first-page":"151","volume":"1","author":"CJ Schultz","year":"1995","unstructured":"Schultz CJ, Gaffney DK, Lindstrom MJ, Kinsella TJ (1995) Iododeoxyuridine radiosensitization of human glioblastoma cells exposed to acute and chronic gamma irradiation: mechanistic implications and clinical relevance. Cancer J Sci Am 1(2):151\u2013161","journal-title":"Cancer J Sci Am"},{"issue":"1","key":"4709_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12977-016-0247-z","volume":"13","author":"Q Zhang","year":"2016","unstructured":"Zhang Q, Mi Z, Huang Y, Ma L, Ding J, Wang J, Zhang Y, chen Y, Zhou J, Guo F, Li X, Cen S, (2016) 2-thio-6-azauridine inhibits Vpu mediated BST-2 degradation. Retrovirology 13(1):13. https:\/\/doi.org\/10.1186\/s12977-016-0247-z","journal-title":"Retrovirology"},{"key":"4709_CR17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.procbio.2017.12.004","volume":"66","author":"MM Gavara","year":"2018","unstructured":"Gavara MM, Zaveri K, Badana AK, Gugalavath S, Amajala KC, Patnala K, Malla RR (2018) A novel small molecule inhibitor of CD151 inhibits proliferation of metastatic triple negative breast cancer cell lines. Process Biochem 66:254\u2013262. https:\/\/doi.org\/10.1016\/j.procbio.2017.12.004","journal-title":"Process Biochem"},{"key":"4709_CR18","doi-asserted-by":"publisher","first-page":"121534","DOI":"10.1016\/j.lfs.2023.121534","volume":"320","author":"R Marni","year":"2023","unstructured":"Marni R, Malla M, Chakraborty A, Malla R (2023) Proteomic profiling and ROC analysis identify CD151 and ELAVL1 as potential therapy response markers for the antiviral drug in resistant TNBC. Life Sci 320:121534","journal-title":"Life Sci"},{"issue":"26","key":"4709_CR19","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1200\/jco.2014.55.1366","volume":"32","author":"ZS Morris","year":"2014","unstructured":"Morris ZS, Harari PM (2014) Interaction of radiation therapy with molecular targeted agents. J Clin Oncol 32(26):2886\u20132893. https:\/\/doi.org\/10.1200\/jco.2014.55.1366","journal-title":"J Clin Oncol"},{"issue":"23","key":"4709_CR20","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"R Bayat Mokhtari","year":"2017","unstructured":"Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H (2017) Combination therapy in combating cancer. Oncotarget 8(23):38022\u201338043. https:\/\/doi.org\/10.18632\/oncotarget.16723","journal-title":"Oncotarget"},{"key":"4709_CR21","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.biopha.2017.04.027","volume":"91","author":"S Kumari","year":"2017","unstructured":"Kumari S, Badana AK, Mohan GM, Shailender Naik G, Malla R (2017) Synergistic effects of coralyne and paclitaxel on cell migration and proliferation of breast cancer cells lines. Biomed Pharmacother 91:436\u2013445. https:\/\/doi.org\/10.1016\/j.biopha.2017.04.027","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"4709_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.21037\/atm.2019.12.114","volume":"8","author":"ZR Zhou","year":"2020","unstructured":"Zhou ZR, Wang XY, Yu XL, Mei X, Chen XX, Hu QC, Yang ZZ, Guo XM (2020) Building radiation-resistant model in triple-negative breast cancer to screen radioresistance-related molecular markers. Ann Translat Med 8(4):108. https:\/\/doi.org\/10.21037\/atm.2019.12.114","journal-title":"Ann Translat Med"},{"key":"4709_CR23","doi-asserted-by":"publisher","first-page":"107681","DOI":"10.1016\/j.jmgm.2020.107681","volume":"100","author":"M Akella","year":"2020","unstructured":"Akella M, Malla R (2020) Molecular modeling and in vitro study on pyrocatechol as potential pharmacophore of CD151 inhibitor. J Mole Graph Model 100:107681. https:\/\/doi.org\/10.1016\/j.jmgm.2020.107681","journal-title":"J Mole Graph Model"},{"issue":"3","key":"4709_CR24","doi-asserted-by":"publisher","first-page":"e00149","DOI":"10.1002\/prp2.149","volume":"3","author":"J Foucquier","year":"2015","unstructured":"Foucquier J, Guedj M (2015) Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect 3(3):e00149. https:\/\/doi.org\/10.1002\/prp2.149","journal-title":"Pharmacol Res Perspect"},{"key":"4709_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20235881","author":"L Cechakova","year":"2019","unstructured":"Cechakova L, Ondrej M, Pavlik V, Jost P, Cizkova D, Bezrouk A, Pejchal J, Amaravadi RK, Winkler JD, Tichy A (2019) A potent autophagy inhibitor (Lys05) enhances the impact of ionizing radiation on human lung cancer cells H1299. Int J Mole Sci. https:\/\/doi.org\/10.3390\/ijms20235881","journal-title":"Int J Mole Sci"},{"issue":"4","key":"4709_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.4048\/jbc.2016.19.4.372","volume":"19","author":"A Badana","year":"2016","unstructured":"Badana A, Chintala M, Varikuti G, Pudi N, Kumari S, Kappala VR, Malla RR (2016) Lipid raft integrity is required for survival of triple negative breast cancer cells. J Breast Cancer 19(4):372\u2013384. https:\/\/doi.org\/10.4048\/jbc.2016.19.4.372","journal-title":"J Breast Cancer"},{"key":"4709_CR27","doi-asserted-by":"publisher","DOI":"10.4172\/2324-9110.1000186","author":"G Devi","year":"2017","unstructured":"Devi G, Badana A, Madhuri Ch MMP, Naik S (2017) Knockdown of CD151 gene expression reduces survival of estrogen receptor positive breast cancer cells. J Clin Exp Oncol. https:\/\/doi.org\/10.4172\/2324-9110.1000186","journal-title":"J Clin Exp Oncol"},{"issue":"2","key":"4709_CR28","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/jcb.29369","volume":"121","author":"G Shailender","year":"2020","unstructured":"Shailender G, Patanla K, Malla RR (2020) ShRNA-mediated matrix metalloproteinase-2 gene silencing protects normal cells and sensitizes cancer cells against ionizing-radiation induced damage. J Cell Biochem 121(2):1332\u20131352. https:\/\/doi.org\/10.1002\/jcb.29369","journal-title":"J Cell Biochem"},{"key":"4709_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.biopha.2017.10.045","volume":"97","author":"AK Badana","year":"2018","unstructured":"Badana AK, Chintala M, Gavara MM, Naik S, Kumari S, Kappala VR, Iska BR, Malla RR (2018) Lipid rafts disruption induces apoptosis by attenuating expression of LRP6 and survivin in triple negative breast cancer. Biomed Pharmacother 97:359\u2013368. https:\/\/doi.org\/10.1016\/j.biopha.2017.10.045","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"4709_CR30","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1091\/mbc.E16-01-0017","volume":"27","author":"KM Jacobs","year":"2016","unstructured":"Jacobs KM, Misri S, Meyer B, Raj S, Zobel CL, Sleckman BP, Hallahan DE, Sharma GG (2016) Unique epigenetic influence of H2AX phosphorylation and H3K56 acetylation on normal stem cell radioresponses. Mol Biol Cell 27(8):1332\u20131345. https:\/\/doi.org\/10.1091\/mbc.E16-01-0017","journal-title":"Mol Biol Cell"},{"key":"4709_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.12659\/msmbr.893327","volume":"21","author":"K Liu","year":"2015","unstructured":"Liu K, Liu PC, Liu R, Wu X (2015) Dual AO\/EB staining to detect apoptosis in osteosarcoma cells compared with flow cytometry. Med Sci Monit Basic Res 21:15\u201320. https:\/\/doi.org\/10.12659\/msmbr.893327","journal-title":"Med Sci Monit Basic Res"},{"issue":"9","key":"4709_CR32","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.2174\/1871520617666170103101844","volume":"17","author":"GB Bevara","year":"2017","unstructured":"Bevara GB, Kumar ADN, Koteswramma KL, Badana AK, Kumari S, Yarla NS, Malla RR (2017) C-glycosyl flavone from urginea indica inhibits growth and dissemination of ehrlich ascites carcinoma cells in mice. Anticancer Agents Med Chem 17(9):1256\u20131266. https:\/\/doi.org\/10.2174\/1871520617666170103101844","journal-title":"Anticancer Agents Med Chem"},{"issue":"2","key":"4709_CR33","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/jcb.29369","volume":"121","author":"G Shailender","year":"2020","unstructured":"Shailender G, Patanla K, Malla RR (2020) ShRNA-mediated matrix metalloproteinase-2 gene silencing protects normal cells and sensitizes cancer cells against ionizing-radiation induced damage. J Cell Biochem 121(2):1332\u20131352","journal-title":"J Cell Biochem"},{"issue":"2","key":"4709_CR34","first-page":"162","volume":"8","author":"K Deepak","year":"2021","unstructured":"Deepak K, Kumari S, Malla RR (2021) Marine cyclic dipeptide cyclo (L-Leu-L-Pro) protects normal breast epithelial cells from tBHP-induced oxidative damage by targeting CD151. Arch Breast Cancer 8(2):162\u2013173","journal-title":"Arch Breast Cancer"},{"issue":"1","key":"4709_CR35","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13046-024-03082-z","volume":"43","author":"K Zhang","year":"2024","unstructured":"Zhang K, Zhu Z, Jia R, Wang NA, Shi M, Wang Y, Xiang S, Zhang Q, Xu L (2024) CD151-enriched migrasomes mediate hepatocellular carcinoma invasion by conditioning cancer cells and promoting angiogenesis. J Exp Clin Cancer Res\u202f: CR 43(1):160. https:\/\/doi.org\/10.1186\/s13046-024-03082-z","journal-title":"J Exp Clin Cancer Res : CR"},{"key":"4709_CR36","doi-asserted-by":"publisher","first-page":"121534","DOI":"10.1016\/j.lfs.2023.121534","volume":"320","author":"R Marni","year":"2023","unstructured":"Marni R, Malla M, Chakraborty A, Malla R (2023) Proteomic profiling and ROC analysis identify CD151 and ELAVL1 as potential therapy response markers for the antiviral drug in resistant TNBC. Life Sci 320:121534. https:\/\/doi.org\/10.1016\/j.lfs.2023.121534","journal-title":"Life Sci"},{"key":"4709_CR37","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot095497","author":"P Kumar","year":"2018","unstructured":"Kumar P, Nagarajan A, Uchil PD (2018) Analysis of cell viability by the lactate dehydrogenase assay. Cold Spring Harb Protoc. https:\/\/doi.org\/10.1101\/pdb.prot095497","journal-title":"Cold Spring Harb Protoc"},{"key":"4709_CR38","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot087312","author":"LC Crowley","year":"2016","unstructured":"Crowley LC, Waterhouse NJ (2016) Detecting cleaved caspase-3 in apoptotic cells by flow cytometry. Cold Spring Harb Protoc. https:\/\/doi.org\/10.1101\/pdb.prot087312","journal-title":"Cold Spring Harb Protoc"},{"issue":"6","key":"4709_CR39","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.3892\/or.2018.6714","volume":"40","author":"YS Ko","year":"2018","unstructured":"Ko YS, Jin H, Lee JS, Park SW, Chang KC, Kang KM, Jeong BK, Kim HJ (2018) Radioresistant breast cancer cells exhibit increased resistance to chemotherapy and enhanced invasive properties due to cancer stem cells. Oncol Rep 40(6):3752\u20133762. https:\/\/doi.org\/10.3892\/or.2018.6714","journal-title":"Oncol Rep"},{"key":"4709_CR40","doi-asserted-by":"publisher","first-page":"101304","DOI":"10.1016\/j.tranon.2021.101304","volume":"18","author":"SY Xiao","year":"2022","unstructured":"Xiao SY, Yan ZG, Zhu XD, Qiu J, Lu YC, Zeng FR (2022) LncRNA DLGAP1-AS2 promotes the radioresistance of rectal cancer stem cells by upregulating CD151 expression via E2F1. Translational oncology 18:101304. https:\/\/doi.org\/10.1016\/j.tranon.2021.101304","journal-title":"Translational oncology"},{"key":"4709_CR41","doi-asserted-by":"publisher","first-page":"731535","DOI":"10.3389\/fonc.2021.731535","volume":"11","author":"Y Li","year":"2021","unstructured":"Li Y, Zhan Z, Yin X, Fu S, Deng X (2021) Targeted therapeutic strategies for triple-negative breast cancer. Front Oncol 11:731535. https:\/\/doi.org\/10.3389\/fonc.2021.731535","journal-title":"Front Oncol"},{"issue":"1","key":"4709_CR42","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K (2022) Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer 21(1):28. https:\/\/doi.org\/10.1186\/s12943-021-01489-2","journal-title":"Mol Cancer"},{"key":"4709_CR43","doi-asserted-by":"publisher","first-page":"977660","DOI":"10.3389\/fphar.2022.977660","volume":"13","author":"J Zhang","year":"2022","unstructured":"Zhang J, Xia Y, Zhou X, Yu H, Tan Y, Du Y, Zhang Q, Wu Y (2022) Current landscape of personalized clinical treatments for triple-negative breast cancer. Front Pharmacol 13:977660. https:\/\/doi.org\/10.3389\/fphar.2022.977660","journal-title":"Front Pharmacol"},{"issue":"1","key":"4709_CR44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13058-023-01615-6","volume":"25","author":"C Mani","year":"2023","unstructured":"Mani C, Acharya G, Saamarthy K, Ochola D, Mereddy S, Pruitt K, Manne U, Palle K (2023) Racial differences in RAD51 expression are regulated by miRNA-214-5P and its inhibition synergizes with olaparib in triple-negative breast cancer. Breast Cancer Res 25(1):44. https:\/\/doi.org\/10.1186\/s13058-023-01615-6","journal-title":"Breast Cancer Res"},{"key":"4709_CR45","doi-asserted-by":"publisher","first-page":"166300","DOI":"10.1016\/j.bbadis.2021.166300","volume":"2","author":"C Mani","year":"1868","unstructured":"Mani C, Tripathi K, Omy TR, Reedy M, Manne U (1868) Palle K (2022) GLI1-targeting drugs induce replication stress and homologous recombination deficiency and synergize with PARP-targeted therapies in triple negative breast cancer cells. Biochim Biophys Acta 2:166300. https:\/\/doi.org\/10.1016\/j.bbadis.2021.166300","journal-title":"Biochim Biophys Acta"},{"issue":"14","key":"4709_CR46","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1158\/1078-0432.Ccr-16-3083","volume":"23","author":"DR Liston","year":"2017","unstructured":"Liston DR, Davis M (2017) Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies. Clin Cancer Res\u202f: Off J Am Assoc Cancer Res 23(14):3489\u20133498. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-3083","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"issue":"7","key":"4709_CR47","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00432-012-1185-3","volume":"138","author":"M Nitsche","year":"2012","unstructured":"Nitsche M, Christiansen H, Lederer K, Griesinger F, Schmidberger H, Pradier O (2012) Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study. J Cancer Res Clin Oncol 138(7):1113\u20131120. https:\/\/doi.org\/10.1007\/s00432-012-1185-3","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"4709_CR48","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1080\/15257770.2012.723770","volume":"31","author":"MA Stackhouse","year":"2012","unstructured":"Stackhouse MA, Gilbert KS, Scoggins JW, Waud WR (2012) Preclinical combination therapy of clofarabine plus radiation. Nucleosides, Nucleotides Nucleic Acids 31(9):692\u2013705. https:\/\/doi.org\/10.1080\/15257770.2012.723770","journal-title":"Nucleosides, Nucleotides Nucleic Acids"},{"issue":"4","key":"4709_CR49","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00411-022-00991-5","volume":"61","author":"B Pszcz\u00f3\u0142kowska","year":"2022","unstructured":"Pszcz\u00f3\u0142kowska B, Olejarz W, Filipek M, Tartas A, Kubiak-Tomaszewska G, \u017bo\u0142nierzak A, \u017bycie\u0144ska K, Ginter J, Lorenc T, Brzozowska B (2022) Exosome secretion and cellular response of DU145 and PC3 after exposure to alpha radiation. Radiat Environ Biophys 61(4):639\u2013650. https:\/\/doi.org\/10.1007\/s00411-022-00991-5","journal-title":"Radiat Environ Biophys"},{"key":"4709_CR50","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201903176","author":"CS Ferranti","year":"2020","unstructured":"Ferranti CS, Cheng J, Thompson C, Zhang J, Rotolo JA, Buddaseth S, Fuks Z, Kolesnick RN (2020) Fusion of lysosomes to plasma membrane initiates radiation-induced apoptosis. J Cell Biol. https:\/\/doi.org\/10.1083\/jcb.201903176","journal-title":"J Cell Biol"},{"issue":"11","key":"4709_CR51","doi-asserted-by":"publisher","first-page":"e0166848","DOI":"10.1371\/journal.pone.0166848","volume":"11","author":"K Maeda","year":"2016","unstructured":"Maeda K, Yasui H, Yamamori T, Matsuura T, Takao S, Suzuki M, Matsuda A, Inanami O, Shirato H (2016) A Nucleoside anticancer drug, 1-(3-C-Ethynyl-\u03b2-D-Ribo-Pentofuranosyl)cytosine, induces depth-dependent enhancement of tumor cell death in spread-out bragg peak (SOBP) of ##eam. PLoS ONE 11(11):e0166848. https:\/\/doi.org\/10.1371\/journal.pone.0166848","journal-title":"PLoS ONE"},{"issue":"3","key":"4709_CR52","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1177\/1533034615585209","volume":"15","author":"C Gao","year":"2016","unstructured":"Gao C, Wu X, Yan Y, Meng L, Shan D, Li Y, Han B (2016) Sensitization of radiation or gemcitabine-based chemoradiation therapeutic effect by nimotuzumab in pancreatic cancer cells. Technol Cancer Res Treat 15(3):446\u2013452. https:\/\/doi.org\/10.1177\/1533034615585209","journal-title":"Technol Cancer Res Treat"},{"key":"4709_CR53","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3389\/fonc.2020.00452","volume":"10","author":"S Yousefnia","year":"2020","unstructured":"Yousefnia S, Seyed Forootan F, Seyed Forootan S, Nasr Esfahani MH, Gure AO, Ghaedi K (2020) Mechanistic pathways of malignancy in breast cancer stem cells. Front Oncol 10:452. https:\/\/doi.org\/10.3389\/fonc.2020.00452","journal-title":"Front Oncol"},{"key":"4709_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10110456","author":"M Wank","year":"2018","unstructured":"Wank M, Schilling D, Schmid TE, Meyer B, Gempt J, Barz M, Schlegel J, Liesche F, Kessel KA, Wiestler B, Bette S, Zimmer C, Combs SE (2018) Human glioma migration and infiltration properties as a target for personalized radiation medicine. Cancers. https:\/\/doi.org\/10.3390\/cancers10110456","journal-title":"Cancers"},{"issue":"2","key":"4709_CR55","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.critrevonc.2014.05.006","volume":"92","author":"C Moncharmont","year":"2014","unstructured":"Moncharmont C, Levy A, Guy JB, Falk AT, Guilbert M, Trone JC, Alphonse G, Gilormini M, Ardail D, Toillon RA, Rodriguez-Lafrasse C, Magn\u00e9 N (2014) Radiation-enhanced cell migration\/invasion process: a review. Crit Rev Oncol Hematol 92(2):133\u2013142. https:\/\/doi.org\/10.1016\/j.critrevonc.2014.05.006","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"4709_CR56","doi-asserted-by":"publisher","first-page":"e11222","DOI":"10.1371\/journal.pone.0011222","volume":"5","author":"I Sofia Vala","year":"2010","unstructured":"Sofia Vala I, Martins LR, Imaizumi N, Nunes RJ, Rino J, Kuonen F, Carvalho LM, R\u00fcegg C, Grillo IM, Barata JT, Mareel M, Santos SC (2010) Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS ONE 5(6):e11222. https:\/\/doi.org\/10.1371\/journal.pone.0011222","journal-title":"PLoS ONE"},{"key":"4709_CR57","doi-asserted-by":"publisher","first-page":"153303381984070","DOI":"10.1177\/1533033819840706","volume":"18","author":"L Pan","year":"2019","unstructured":"Pan L, Wan M, Zheng W, Wu R, Tang W, Zhang X, Yang T, Ye C (2019) Intrabeam radiation inhibits proliferation, migration, and invasiveness and promotes apoptosis of mcf-7 breast cancer cells. Technol Cancer Res Treat 18:1533033819840706. https:\/\/doi.org\/10.1177\/1533033819840706","journal-title":"Technol Cancer Res Treat"},{"key":"4709_CR58","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3389\/fonc.2019.00391","volume":"9","author":"K Konings","year":"2019","unstructured":"Konings K, Vandevoorde C, Belmans N, Vermeesen R, Baselet B, Walleghem MV, Janssen A, Isebaert S, Baatout S, Haustermans K, Moreels M (2019) The combination of particle irradiation with the hedgehog inhibitor GANT61 differently modulates the radiosensitivity and migration of cancer cells compared to x-ray irradiation. Front Oncol 9:391. https:\/\/doi.org\/10.3389\/fonc.2019.00391","journal-title":"Front Oncol"},{"issue":"3","key":"4709_CR59","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.3892\/ol.2015.3458","volume":"10","author":"ST Elias","year":"2015","unstructured":"Elias ST, Borges GA, R\u00eago DF, Silva OE, LF, Avelino S, Nunes de Matos Neto J, Simeoni LA, Guerra ENS, (2015) Combined paclitaxel, cisplatin and fluorouracil therapy enhances ionizing radiation effects, inhibits migration and induces G0\/G1 cell cycle arrest and apoptosis in oral carcinoma cell lines. Oncol Lett 10(3):1721\u20131727. https:\/\/doi.org\/10.3892\/ol.2015.3458","journal-title":"Oncol Lett"},{"issue":"5","key":"4709_CR60","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3892\/ijo.2014.2614","volume":"45","author":"AL Hein","year":"2014","unstructured":"Hein AL, Ouellette MM, Yan Y (2014) Radiation-induced signaling pathways that promote cancer cell survival (Review). Int J Oncol 45(5):1813\u20131819. https:\/\/doi.org\/10.3892\/ijo.2014.2614","journal-title":"Int J Oncol"},{"issue":"2","key":"4709_CR61","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3109\/15368378.2014.992073","volume":"35","author":"SR Tsai","year":"2016","unstructured":"Tsai SR, Sheu BC, Huang PS, Lee SC (2016) The effects of narrow-band middle infrared radiation in enhancing the antitumor activity of paclitaxel. Electromagn Biol Med 35(2):106\u2013114. https:\/\/doi.org\/10.3109\/15368378.2014.992073","journal-title":"Electromagn Biol Med"},{"issue":"4","key":"4709_CR62","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1269\/jrr.10188","volume":"52","author":"S Meike","year":"2011","unstructured":"Meike S, Yamamori T, Yasui H, Eitaki M, Matsuda A, Inanami O (2011) 8-Aminoadenosine enhances radiation-induced cell death in human lung carcinoma A549 cells. J Radiat Res 52(4):456\u2013463","journal-title":"J Radiat Res"},{"issue":"4","key":"4709_CR63","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3978\/j.issn.2072-1439.2014.01.23","volume":"6","author":"FM Kong","year":"2014","unstructured":"Kong FM, Zhao J, Wang J, Faivre-Finn C (2014) Radiation dose effect in locally advanced non-small cell lung cancer. J Thorac Dis 6(4):336\u2013347. https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2014.01.23","journal-title":"J Thorac Dis"},{"issue":"3","key":"4709_CR64","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3892\/or.2021.7924","volume":"45","author":"JY Moon","year":"2021","unstructured":"Moon JY, Ediriweera MK, Ryu JY, Kim HY, Cho SK (2021) Catechol enhances chemo- and radio-sensitivity by targeting AMPK\/Hippo signaling in pancreatic cancer cells. Oncol Rep 45(3):1133\u20131141. https:\/\/doi.org\/10.3892\/or.2021.7924","journal-title":"Oncol Rep"},{"issue":"5","key":"4709_CR65","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/bjc.2012.11","volume":"106","author":"MJ Kwon","year":"2012","unstructured":"Kwon MJ, Park S, Choi JY, Oh E, Kim YJ, Park YH, Cho EY, Kwon MJ, Nam SJ, Im YH, Shin YK, Choi YL (2012) Clinical significance of CD151 overexpression in subtypes of invasive breast cancer. Br J Cancer 106(5):923\u2013930. https:\/\/doi.org\/10.1038\/bjc.2012.11","journal-title":"Br J Cancer"},{"issue":"3","key":"4709_CR66","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.neo.2016.02.003","volume":"18","author":"J Tilghman","year":"2016","unstructured":"Tilghman J, Schiapparelli P, Lal B, Ying M, Quinones-Hinojosa A, Xia S, Laterra J (2016) Regulation of glioblastoma tumor-propagating cells by the integrin partner tetraspanin CD151. Neoplasia (New York, NY) 18(3):185\u2013198. https:\/\/doi.org\/10.1016\/j.neo.2016.02.003","journal-title":"Neoplasia (New York, NY)"},{"key":"4709_CR67","doi-asserted-by":"publisher","first-page":"50","DOI":"10.32768\/abc.20229150-65","volume":"9","author":"R Malla","year":"2022","unstructured":"Malla R, Marni R, Gavara CA (2022) Antiviral drug 2-thio-6-azauridine sensitizes paclitaxel-resistant triple negative breast cancer cells by targeting mammosphere formation and ABC transporters. Arch Breast Cancer 9:50\u201365. https:\/\/doi.org\/10.32768\/abc.20229150-65","journal-title":"Arch Breast Cancer"},{"key":"4709_CR68","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ebiom.2019.10.025","volume":"49","author":"W Lin","year":"2019","unstructured":"Lin W, Liu J, Chen J, Li J, Qiu S, Ma J, Lin X, Zhang L, Wu J (2019) Peptides of tetraspanin oncoprotein CD151 trigger active immunity against primary tumour and experimental lung metastasis. EBioMedicine 49:133\u2013144. https:\/\/doi.org\/10.1016\/j.ebiom.2019.10.025","journal-title":"EBioMedicine"},{"issue":"8","key":"4709_CR69","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00018-019-03014-7","volume":"76","author":"S Hwang","year":"2019","unstructured":"Hwang S, Takimoto T, Hemler ME (2019) Integrin-independent support of cancer drug resistance by tetraspanin CD151. Cell Mol Life Sci 76(8):1595\u20131604. https:\/\/doi.org\/10.1007\/s00018-019-03014-7","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"4709_CR70","doi-asserted-by":"publisher","first-page":"15639","DOI":"10.1038\/s41598-020-72722-z","volume":"10","author":"H Fu","year":"2020","unstructured":"Fu H, Zhang Y, Liao C, Mao L, Wang Z, Hong N (2020) Investigating PM(2.5) responses to other air pollutants and meteorological factors across multiple temporal scales. Sci Rep 10(1):15639. https:\/\/doi.org\/10.1038\/s41598-020-72722-z","journal-title":"Sci Rep"},{"issue":"5","key":"4709_CR71","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00784-016-1911-3","volume":"21","author":"JC Nienstedt","year":"2017","unstructured":"Nienstedt JC, Gr\u00f6be A, Lebok P, B\u00fcscheck F, Clauditz T, Simon R, Heumann A, Sauter G, Moebius C, M\u00fcnscher A, Knecht R, Blessmann M, Heiland M, Pflug C (2017) CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer. Clin Oral Invest 21(5):1503\u20131508. https:\/\/doi.org\/10.1007\/s00784-016-1911-3","journal-title":"Clin Oral Invest"},{"issue":"6","key":"4709_CR72","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/jso.23249","volume":"107","author":"D Lee","year":"2013","unstructured":"Lee D, Suh YL, Park TI, Do IG, Seol HJ, Nam DH, Kim ST (2013) Prognostic significance of tetraspanin CD151 in newly diagnosed glioblastomas. J Surg Oncol 107(6):646\u2013652","journal-title":"J Surg Oncol"},{"issue":"10","key":"4709_CR73","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/bjc.2011.80","volume":"104","author":"M Voss","year":"2011","unstructured":"Voss M, Gordon N, Maloney S, Ganesan R, Ludeman L, McCarthy K, Gornall R, Schaller G, Wei W, Berditchevski F (2011) Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer. Br J Cancer 104(10):1611\u20131618","journal-title":"Br J Cancer"},{"issue":"5","key":"4709_CR74","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1245\/s10434-016-5504-9","volume":"23","author":"OM Fisher","year":"2016","unstructured":"Fisher OM, Levert-Mignon AJ, Lehane CW, Botelho NK, Maag JLV, Thomas ML, Edwards M, Lord SJ, Bobryshev YV, Whiteman DC, Lord RV (2016) CD151 gene and protein expression provides independent prognostic information for patients with adenocarcinoma of the esophagus and gastroesophageal junction treated by esophagectomy. Ann Surg Oncol 23(5):746\u2013754. https:\/\/doi.org\/10.1245\/s10434-016-5504-9","journal-title":"Ann Surg Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04709-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04709-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04709-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T17:02:16Z","timestamp":1728752536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04709-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["4709"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04709-w","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"assertion":[{"value":"12 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}